IceCure Medical Ltd. Ordinary Shares ICCM

Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.

ICCM hizo una agrupación de acciones (split inverso) de 1:30 el 4 de junio de 2026: cada 30 acciones se juntaron en una. Bajó la cantidad de acciones y subió su precio, pero no el valor total de la inversión.

• Benzinga 17 jun

  IceCure Announces Pricing of $5.5 Million Private Placement Priced At a Premium to the Market Price with a Single Healthcare Focused Institutional Investor

  IceCure Medical Ltd. (NASDAQ: ICCM) announced a $5.5 million private placement of 1.83 million ordinary shares and warrants priced at $3.00 per share, representing a premium to the previous closing price. The offering is expected to close on June 18, 2026, with proceeds intended for working capital and general corporate purposes. The company also agreed to amend previously issued warrants to reduce their exercise price from $16.50 to $3.00 per share, subject to shareholder approval.

  

• Benzinga 17 jun

  IceCure Reports 70% Growth in Active U.S. Commercial Install Base for Breast Cancer Cryoablation Following FDA Clearance

  IceCure Medical reported a 70% increase in its U.S. active commercial install base for ProSense® breast cancer cryoablation systems following FDA marketing authorization in October 2025. The growth is driven by FDA clearance, clinical guideline support from the American Society of Breast Surgeons, increased physician demand demonstrated at major medical conferences, and growing patient awareness through media coverage. The company believes it is in the early stages of a significant commercial opportunity in the U.S. market.